Like this article?
Get your free daily medical news from Physician's First Watch.
Celecoxib Lowers Restenosis in Paclitaxel-Coated Stents
Patients receiving paclitaxel-coated stents had less restenosis at 6 months if they took celecoxib twice daily, the Lancet reports.
Researchers randomized 274 patients undergoing stenting to either 200 mg of celecoxib twice a day or no further adjunctive therapy (all patients received aspirin and clopidogrel). The patients were part of a study assessing the drug's role in reducing neointimal hyperplasia. At 6 months, quantitative angiography revealed less loss in luminal diameter among the celecoxib group (0.49 mm) than among the controls (0.75 mm).
Editorialists as well as the authors caution against applying the results clinically until much larger studies with longer follow-up are undertaken.
Link: Lancet article (Free abstract; full text requires subscription)
Link: Lancet comment (Subscription required)
Published in Physician's First Watch August 20, 2007
Your Remark:
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.